Ptc Therapeutics (PTCT) Gains from Sales and Divestitures (2014 - 2026)

Ptc Therapeutics' Gains from Sales and Divestitures history runs 10 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures rose 14.29% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (up 14.29% YoY), while the FY2025 annual figure was $1.3 million, up 30.16% from the prior year.
• Gains from Sales and Divestitures was $1.2 million for Q1 2026 at Ptc Therapeutics, down from $1.3 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.3 million in Q4 2025 to a low of $426470.0 in Q1 2022.
• Historically, Gains from Sales and Divestitures has averaged $858451.4 across 5 years, with a median of $891879.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Gains from Sales and Divestitures jumped 82.33% in 2023, then climbed 4.68% in 2024.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $504851.0 in 2022, then surged by 82.33% to $920488.0 in 2023, then gained by 4.68% to $963543.0 in 2024, then jumped by 30.16% to $1.3 million in 2025, then declined by 0.67% to $1.2 million in 2026.
• The last three Gains from Sales and Divestitures figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.